LeMaitre Vascular Inc (LMAT) Expected to Post Quarterly Sales of $25.90 Million

Analysts expect LeMaitre Vascular Inc (NASDAQ:LMAT) to announce $25.90 million in sales for the current quarter, Zacks reports. Three analysts have made estimates for LeMaitre Vascular’s earnings. The lowest sales estimate is $25.60 million and the highest is $26.12 million. LeMaitre Vascular reported sales of $26.15 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 1%. The company is expected to issue its next earnings report on Wednesday, February 20th.

On average, analysts expect that LeMaitre Vascular will report full year sales of $103.08 million for the current financial year, with estimates ranging from $102.80 million to $103.30 million. For the next financial year, analysts expect that the business will post sales of $110.52 million, with estimates ranging from $109.80 million to $111.30 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover LeMaitre Vascular.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 earnings per share for the quarter, meeting the consensus estimate of $0.21. LeMaitre Vascular had a return on equity of 18.07% and a net margin of 20.52%. The firm had revenue of $24.17 million during the quarter, compared to the consensus estimate of $26.06 million.

Several equities analysts have commented on the company. ValuEngine cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Monday, July 30th. Zacks Investment Research cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Wednesday, August 1st. BidaskClub cut LeMaitre Vascular from a “hold” rating to a “sell” rating in a report on Tuesday, October 9th. Roth Capital cut LeMaitre Vascular from a “buy” rating to a “neutral” rating and upped their price target for the company from $38.00 to $39.00 in a report on Tuesday, October 2nd. Finally, Lake Street Capital cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, October 5th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $35.86.

NASDAQ:LMAT traded down $0.71 during mid-day trading on Thursday, hitting $26.93. 69,061 shares of the company’s stock traded hands, compared to its average volume of 113,326. LeMaitre Vascular has a 12 month low of $26.39 and a 12 month high of $41.28. The company has a market cap of $541.25 million, a price-to-earnings ratio of 26.58, a PEG ratio of 2.24 and a beta of 0.99.

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 6th. Stockholders of record on Tuesday, November 20th will be issued a $0.07 dividend. The ex-dividend date is Monday, November 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 1.04%. LeMaitre Vascular’s payout ratio is presently 32.56%.

In other news, Director Michael H. Thomas sold 20,000 shares of the stock in a transaction that occurred on Tuesday, October 30th. The stock was sold at an average price of $27.93, for a total value of $558,600.00. Following the completion of the transaction, the director now directly owns 20,000 shares of the company’s stock, valued at approximately $558,600. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Chairman George W. Lemaitre sold 14,180 shares of the stock in a transaction that occurred on Wednesday, August 22nd. The stock was sold at an average price of $37.61, for a total value of $533,309.80. Following the completion of the transaction, the chairman now directly owns 3,118,266 shares of the company’s stock, valued at $117,277,984.26. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,681 shares of company stock valued at $1,110,462. 20.30% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Piedmont Investment Advisors LLC bought a new stake in LeMaitre Vascular during the 2nd quarter worth approximately $119,000. Tower Research Capital LLC TRC grew its position in LeMaitre Vascular by 222.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,451 shares of the medical instruments supplier’s stock worth $149,000 after acquiring an additional 3,072 shares during the last quarter. Jane Street Group LLC bought a new stake in LeMaitre Vascular during the 2nd quarter worth approximately $206,000. First Trust Advisors LP bought a new stake in LeMaitre Vascular during the 3rd quarter worth approximately $214,000. Finally, Dynamic Technology Lab Private Ltd bought a new stake in LeMaitre Vascular during the 1st quarter worth approximately $215,000. Institutional investors and hedge funds own 81.37% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

See Also: What are CEFs?

Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply